These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33647441)

  • 1. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns.
    Touafchia A; Bagheri H; Carrié D; Durrieu G; Sommet A; Chouchana L; Montastruc F
    Clin Microbiol Infect; 2021 Feb; 27(5):791.e5-8. PubMed ID: 33647441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
    Garcia P; Revet A; Yrondi A; Rousseau V; Degboe Y; Montastruc F
    Drug Saf; 2020 Dec; 43(12):1315-1322. PubMed ID: 33078372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Kidney Injury and Drugs Prescribed for COVID-19 in Diabetes Patients: A Real-World Disproportionality Analysis.
    Zhou Y; Li J; Wang L; Zhu X; Zhang M; Zheng J
    Front Pharmacol; 2022; 13():833679. PubMed ID: 35370750
    [No Abstract]   [Full Text] [Related]  

  • 4. Potential kidney damage associated with the use of remdesivir for COVID-19: analysis of a pharmacovigilance database.
    Silva NAO; Zara ALSA; Figueras A; Melo DO
    Cad Saude Publica; 2021; 37(10):e00077721. PubMed ID: 34787281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database.
    Gérard AO; Laurain A; Fresse A; Parassol N; Muzzone M; Rocher F; Esnault VLM; Drici MD
    Clin Pharmacol Ther; 2021 Apr; 109(4):1021-1024. PubMed ID: 33340409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
    Orogun L; Chyou TY; Nishtala PS
    Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data.
    Tang H; Zhou L; Li X; Kinlaw AC; Yang JY; Moon AM; Barnes EL; Wang T
    Int J Clin Pharm; 2021 Aug; 43(4):1116-1122. PubMed ID: 34328585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.
    Gérard A; Romani S; Fresse A; Viard D; Parassol N; Granvuillemin A; Chouchana L; Rocher F; Drici MD;
    Therapie; 2020; 75(4):371-379. PubMed ID: 32418730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.
    Izcovich A; Siemieniuk RA; Bartoszko JJ; Ge L; Zeraatkar D; Kum E; Qasim A; Khamis AM; Rochwerg B; Agoritsas T; Chu DK; McLeod SL; Mustafa RA; Vandvik P; Brignardello-Petersen R
    BMJ Open; 2022 Mar; 12(3):e048502. PubMed ID: 35236729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database.
    Jung SY; Kim MS; Li H; Lee KH; Koyanagi A; Solmi M; Kronbichler A; Dragioti E; Tizaoui K; Cargnin S; Terrazzino S; Hong SH; Abou Ghayda R; Kim NK; Chung SK; Jacob L; Salem JE; Yon DK; Lee SW; Kostev K; Kim AY; Jung JW; Choi JY; Shin JS; Park SJ; Choi SW; Ban K; Moon SH; Go YY; Shin JI; Smith L
    Clin Transl Sci; 2022 Feb; 15(2):501-513. PubMed ID: 34719115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review.
    Qomara WF; Primanissa DN; Amalia SH; Purwadi FV; Zakiyah N
    Int J Gen Med; 2021; 14():8557-8571. PubMed ID: 34849001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir.
    Yin G; Zhang C; Jin H
    JMIR Public Health Surveill; 2020 Jul; 6(3):e19538. PubMed ID: 32589146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
    Maciorowski D; Idrissi SZE; Gupta Y; Medernach BJ; Burns MB; Becker DP; Durvasula R; Kempaiah P
    SLAS Discov; 2020 Dec; 25(10):1108-1122. PubMed ID: 32942923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials.
    Siordia JA; Bernaba M; Yoshino K; Ulhaque A; Kumar S; Bernaba M; Bergin E
    SN Compr Clin Med; 2020; 2(8):1120-1131. PubMed ID: 32838169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
    Ader F; Peiffer-Smadja N; Poissy J; Bouscambert-Duchamp M; Belhadi D; Diallo A; Delmas C; Saillard J; Dechanet A; Mercier N; Dupont A; Alfaiate T; Lescure FX; Raffi F; Goehringer F; Kimmoun A; Jaureguiberry S; Reignier J; Nseir S; Danion F; Clere-Jehl R; Bouiller K; Navellou JC; Tolsma V; Cabié A; Dubost C; Courjon J; Leroy S; Mootien J; Gaci R; Mourvillier B; Faure E; Pourcher V; Gallien S; Launay O; Lacombe K; Lanoix JP; Makinson A; Martin-Blondel G; Bouadma L; Botelho-Nevers E; Gagneux-Brunon A; Epaulard O; Piroth L; Wallet F; Richard JC; Reuter J; Staub T; Lina B; Noret M; Andrejak C; Lê MP; Peytavin G; Hites M; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Clin Microbiol Infect; 2021 Dec; 27(12):1826-1837. PubMed ID: 34048876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
    Zekarias A; Watson S; Vidlin SH; Grundmark B
    Drug Saf; 2020 Dec; 43(12):1309-1314. PubMed ID: 32978702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System.
    Li X; Zhou L; Gaggl M; Kinlaw AC; Gou Z; Xu Y; Wei J; Wang T
    Int J Clin Pharm; 2023 Apr; 45(2):509-514. PubMed ID: 36964312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project.
    Devgun JM; Zhang R; Brent J; Wax P; Burkhart K; Meyn A; Campleman S; Abston S; Aldy K;
    JAMA Netw Open; 2023 Feb; 6(2):e2255815. PubMed ID: 36787141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase.
    Saint-Gerons DM; Tabarés-Seisdedos R
    Eur J Clin Pharmacol; 2021 Oct; 77(10):1513-1521. PubMed ID: 33938974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.